Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Once the 3-71 data is available Missling indicates that Anavex may move forward with FTD and any other related dementia indication. "So, we have mentioned that we will move ahead with frontotemporal dementia, but we'd like to have really the solid phase 1 data in hand before we say we commit to this. And -- but we'll definitely move forward with FTD or any other related dementia indication." When the phase 1 3-71 data is presented, maybe we will learn more about what other FTD related indications Anavex may explore. However, from the recent Nell Rebowe presentation, we may surmise that positive 3-71 data for FTD will indicate promise for a future Anavex clinical trial for ALS. We may also learn whether any prospective Anavex ALS trial will involve either 2-73 or 3-71 or both.

Many thanks sokol for the excellent in-depth analysis. The good news is we will not have to wait long for the A3-71 Ph-1 data on FTD, and maybe Missling will reveal what the next A3-71 CNS target (ALS?) shortly after the FTD PR.